NCT03970382 2022-08-18
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
Phase 1 Suspended
PACT Pharma, Inc.
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center